HB-adMSCs for the Treatment of Crohn's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Crohn Disease (CD)
Interventions
DRUG

HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells

Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells). Dose: 200 million cells (+/- 20%) suspended in 20mL 0.9% sodium chloride. Route: Intravenous. Regimen: Weeks 0, 2, 4, 8, 12, and 16. Preparation: HB-adMSCs syringe should be diluted in 250 mL 0.9% sodium chloride (for a total volume of 270 mL).

DRUG

0.9% sodium chloride

0.9% sodium chloride Dose: N/A - 20mL 0.9% sodium chloride. Route: Intravenous. Regimen: Weeks 0, 2, 4, 8, 12, and 16. Preparation: Placebo syringe should be diluted in 250 mL 0.9% sodium chloride (for a total volume of 270 mL).

Trial Locations (1)

77478

RECRUITING

Hope Biosciences Research Foundation, Sugar Land

All Listed Sponsors
lead

Hope Biosciences Research Foundation

INDUSTRY

NCT07077746 - HB-adMSCs for the Treatment of Crohn's Disease | Biotech Hunter | Biotech Hunter